Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
- John M Ringman,
- Sally A Frautschy,
- Edmond Teng,
- Aynun N Begum,
- Jenny Bardens,
- Maryam Beigi,
- Karen H Gylys,
- Vladimir Badmaev,
- Dennis D Heath,
- Liana G Apostolova,
- Verna Porter,
- Zeba Vanek,
- Gad A Marshall,
- Gerhard Hellemann,
- Catherine Sugar,
- Donna L Masterman,
- Thomas J Montine,
- Jeffrey L Cummings,
- Greg M Cole
- … show all 19 hide
Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidate for treating human AD. The purpose of the current study is to generate tolerability and preliminary clinical and biomarker efficacy data on curcumin in persons with AD.
We performed a 24-week randomized, double blind, placebo-controlled study of Curcumin C3 Complex® with an open-label extension to 48 weeks. Thirty-six persons with mild-to-moderate AD were randomized to receive placebo, 2 grams/day, or 4 grams/day of oral curcumin for 24 weeks. For weeks 24 through 48, subjects that were receiving curcumin continued with the same dose, while subjects previously receiving placebo were randomized in a 1:1 ratio to 2 grams/day or 4 grams/day. The primary outcome measures were incidence of adverse events, changes in clinical laboratory tests and the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at 24 weeks in those completing the study. Secondary outcome measures included the Neuropsychiatric Inventory (NPI), the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale, levels of Aβ1-40 and Aβ1-42 in plasma and levels of Aβ1-42, t-tau, p-tau181 and F2-isoprostanes in cerebrospinal fluid. Plasma levels of curcumin and its metabolites up to four hours after drug administration were also measured.
Mean age of completers (n = 30) was 73.5 years and mean Mini-Mental Status Examination (MMSE) score was 22.5. One subject withdrew in the placebo (8%, worsened memory) and 5/24 subjects withdrew in the curcumin group (21%, 3 due to gastrointestinal symptoms). Curcumin C3 Complex® was associated with lowered hematocrit and increased glucose levels that were clinically insignificant. There were no differences between treatment groups in clinical or biomarker efficacy measures. The levels of native curcumin measured in plasma were low (7.32 ng/mL).
Curcumin was generally well-tolerated although three subjects on curcumin withdrew due to gastrointestinal symptoms. We were unable to demonstrate clinical or biochemical evidence of efficacy of Curcumin C3 Complex® in AD in this 24-week placebo-controlled trial although preliminary data suggest limited bioavailability of this compound.
ClinicalTrials.gov Identifier: NCT00099710.
- Thies W, Bleiler L: 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011, 7:208–244. CrossRef
- Reddy AC, Lokesh BR: Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem 1992, 111:117–124.
- Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR: Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64:1152–1156. CrossRef
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al.: Inflammation in Alzheimer's disease. Neurobiol Aging 2000, 21:383–421. CrossRef
- Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL: A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005, 2:131–136. CrossRef
- Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA: Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008, 326:196–208. CrossRef
- Kim DS, Park SY, Kim JK: Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1–42) insult. Neurosci Lett 2001, 303:57–61. CrossRef
- Ono K, Hasegawa K, Naiki H, Yamada M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004, 75:742–750. CrossRef
- Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370–8377.
- Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007, 102:1095–1104. CrossRef
- Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001, 7:1894–1900.
- NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024–37–1). (Major Component 79%-85% Curcumin CAS No, 458–37–7) in F344/N Rats and B6C3F1 Mice (Feed Studies) Natl Toxicol Program Tech Rep Ser 1993, 427:1–275.
- Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington: American Psychiatric Association; 1994.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939–944. CrossRef
- Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997,11(Suppl 2):S13–21. CrossRef
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308–2314. CrossRef
- Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997,11(Suppl 2):S33–39. CrossRef
- Milatovic D, VanRollins M, Li K, Montine KS, Montine TJ: Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 827:88–93. CrossRef
- Heath DD, Pruitt MA, Brenner DE, Rock CL: Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 783:287–295. CrossRef
- Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP: Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004, 90:1011–1015. CrossRef
- Pan MH, Huang TM, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999, 27:486–494.
- Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001, 22:993–1005. CrossRef
- Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P: Antioxidants for Alzheimer Disease:a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol, in press.
- Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S: A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 2008, 70:445–449. CrossRef
- Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V: Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008, 28:110–113. CrossRef
- Kokjohn TA, Roher AE: Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 2009, 5:340–347. CrossRef
- Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Alzheimer's Research & Therapy
- Online Date
- October 2012
- Online ISSN
- BioMed Central
- Additional Links
- John M Ringman (1) (2)
- Sally A Frautschy (1) (2) (3) (4)
- Edmond Teng (1) (2) (3) (4)
- Aynun N Begum (2) (3)
- Jenny Bardens (1) (2)
- Maryam Beigi (1)
- Karen H Gylys (1) (5)
- Vladimir Badmaev (6)
- Dennis D Heath (7)
- Liana G Apostolova (1) (2)
- Verna Porter (2)
- Zeba Vanek (2)
- Gad A Marshall (8)
- Gerhard Hellemann (9)
- Catherine Sugar (9)
- Donna L Masterman (10)
- Thomas J Montine (11)
- Jeffrey L Cummings (12)
- Greg M Cole (1) (2) (3) (4)
- Author Affiliations
- 1. Mary S. Easton Center for Alzheimer’s Disease Research, David Geffen School of Medicine at UCLA, 10911 Weyburn Ave., #200, Los Angeles, CA, 90095-7226, USA
- 2. UCLA Department of Neurology, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Los Angeles, CA, 90095-1769, USA
- 3. UCLA Department of Medicine, 757 Westwood Plaza, Los Angeles, CA, 90095, USA
- 4. Geriatric Research Education and Clinical Center, W LA Veterans Administration Medical Center, 11301 Wilshire Blvd., Bldg. 113, Room 312, Los Angeles, CA, 90073, USA
- 5. UCLA School of Nursing, Box 956919, 6-2668 Factor Bldg., Los Angeles, CA, 90095-6919, USA
- 6. AMH Corporation, 1440-6 Forest Hill Road, Staten Island, NY, 10314, USA
- 7. Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, CA, 92093-0901, USA
- 8. Center for Alzheimer Research and Treatment, Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115, USA
- 9. UCLA Semel Institute for Psychiatry and Human Behavior, Box 951759, C9-432 Semel, Los Angeles, CA, 90095-1759, USA
- 10. F. Hoffman-La Roche, Ltd, Grenzacherstrasse 183, Bldg/Room 74/3W.306B, 4070, Basel, Switzerland
- 11. Department of Neuropathology, University of Washington Medical Center, Room C-516, Box 357470, Seattle, WA, 98195, USA
- 12. Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W. Bonneville, Las Vegas, NV, 89106, USA